﻿<?xml version="1.0" encoding="utf-8"?><rss version="2.0"><channel><title>Kenneth8788's Xanga</title><link>http://kenneth8788.xanga.com/</link><description>Latest Xanga weblog from Kenneth8788</description><language>zh-hk</language><ttl>60</ttl><image><title>The Weblog Community</title><url>http://s.xanga.com/images/xangalogobutton.gif</url><link>http://kenneth8788.xanga.com/</link></image><item><title>Monday, April 02, 2012</title><link>http://kenneth8788.xanga.com/760862617/item/</link><guid>http://kenneth8788.xanga.com/760862617/item/</guid><pubDate>Mon, 02 Apr 2012 14:05:40 GMT</pubDate><description>黃昏的約會 &lt;br /&gt;&lt;br /&gt;把「老人癡呆」改稱為「腦退化症」的那個人，為世上造了很大的福。 &lt;br /&gt;家裏的父親開始腦退化？像一闋淡淡的哀歌。每天你發現失去了他一點點。一天比一天，他離你遠，一天比一天荒涼。 &lt;br /&gt;本來父親很健談，他漸沉吟不語。本來很開懷，時時說笑話，他此刻時時在沉思。本來他能豪飲啤酒，現在他只能喝一杯稀淡的蜜糖，持杯的手開始顫抖。 &lt;br /&gt;他沒有病，只是對人生有點困惑。何不換一個角度看這一切？生命本來是一個謎，當你初來這個世界，你不明白。你眼前的父親教會了你：何謂生老病死，什麼叫恩義情仇。你成長，他把着你的小手扶你上路，你曾經倉皇跌倒，他一把扶起你，勸慰你的嚎哭──不要怕，前面的路還很艱嶇，但爸爸和你一起同行，他說。 &lt;br /&gt;父親沒有爽約，他帶過你攀岩石，看浪花，與你一起騎自行車。在日落的時候，幼小的你，看見他怔怔凝視着天邊的雲彩，沒有說話。像想起他的前半生，想起他的童年和你早逝的祖父，也就是他自己的父親。你問他為什麼不說話，他撫摸你的腦瓜子，嘆一口氣，搖搖頭，說：沒什麼，上路吧，讓我們回家。 &lt;br /&gt;他老來坐在客廳，多麼像許多年前看着滿天的晚霞。只是他需要你坐在身邊，握着他的手，用你的臉頰抵着他的肩頭：還記得小時候你帶我攀過那山頭嗎？親愛的爸爸，從前的路，你帶我攀涉過，往日的教誨，你在我耳邊叮嚀，我一度以為我懂得生死是什麼，曾經見山是山，見水是水，從何處來，往何處去，但現在我跟你一樣不太明白。 &lt;br /&gt;他茫然，緩緩抬頭看着你。他灰褐而略有白內障的瞳孔燃燒着一閃日漸冷熄下去的蒼燄。不，他沒有病，只是在今生裏他有點過早地過渡到來世，正如許久前，你三個月大，在父親的襁褓裏，他用情深地盯凝着你，看你從前世的濛鴻中醒來，對你母親說，看，這是我們的孩子。 &lt;br /&gt;腦退化症不是病。只是生命在幼年，是一幅蠟筆畫，盛年是一幅絢爛的油畫。老年只是改習水墨，而在煙水迷茫之處，一片淡綻的曖昧渲化，最終沒入了濛鴻。腦退化的父親，只是化了諸般色相，只是留白的地方最是動人。緊握着他的手，你在耳邊告訴他：爸爸，謝謝你，人生的妙諦，雖你都忘懷，我卻永記你的大愛，像那天我們擁有的黃昏，西天最迷人的一片雲彩。 &lt;br /&gt;&lt;br /&gt;（陶傑） &lt;br /&gt;&lt;br /&gt;&lt;br /&gt;P.S 真的寫得好好... 才子認真起來真的好厲害....</description><comments>http://kenneth8788.xanga.com/760862617/item/#firstcomment</comments></item><item><title>Monday, March 19, 2012</title><link>http://kenneth8788.xanga.com/760010931/item/</link><guid>http://kenneth8788.xanga.com/760010931/item/</guid><pubDate>Mon, 19 Mar 2012 01:18:22 GMT</pubDate><description>下雨了。&lt;br /&gt;這個濕度,&lt;br /&gt;這個味道,&lt;br /&gt;不論你身在哪裡,&lt;br /&gt;回憶都一直會在那兒等候著你。&lt;br /&gt;&lt;br /&gt;沒甚麼,&lt;br /&gt;就只不過在一個下雨的早晨,&lt;br /&gt;把那感性的觸角,&lt;br /&gt;輕輕的,&lt;br /&gt;悄悄的,&lt;br /&gt;慢慢的,&lt;br /&gt;伸展一下。&lt;br /&gt;任由他四處伸展,&lt;br /&gt;任由他四處觸碰,&lt;br /&gt;任由他四處穿梭著。&lt;br /&gt;&lt;br /&gt;又, 回到那些時候。&lt;br /&gt;在背上的觸角,&lt;br /&gt;好像捉到了甚麼東西。&lt;br /&gt;眼前的,&lt;br /&gt;都是笑臉。&lt;br /&gt;一張又一張,&lt;br /&gt;帶著記憶,&lt;br /&gt;帶著味道,&lt;br /&gt;帶著感覺的笑臉。&lt;br /&gt;心, 輕輕的震動了一下。&lt;br /&gt;嘴, 微微的回應了心, 笑了。&lt;br /&gt;&lt;br /&gt;雨點一滴一滴的連繫著一切,&lt;br /&gt;在回憶中穿梭著,&lt;br /&gt;而情感,&lt;br /&gt;遊走在雨點當中。&lt;br /&gt;雨, 停了, 又下&lt;br /&gt;思念卻一直都在。&lt;br /&gt;&lt;br /&gt;有人說,&lt;br /&gt;生活太忙, 忙得忘了自己。&lt;br /&gt;這一個個"忙"字,&lt;br /&gt;和那一個"忘"字,&lt;br /&gt;有著的共通點就是死"亡" 了的"心"吧。&lt;br /&gt;你的心放在那,&lt;br /&gt;感受就在你的生活反映出來。&lt;br /&gt;如你把你的心放在一旁,&lt;br /&gt;看到的只有工作, "忙"就是你的感受;&lt;br /&gt;又如果你把心放在生活的最底,&lt;br /&gt;"忘"記了自己,&lt;br /&gt;生活也不太好過。&lt;br /&gt;還是把"心"放在感"受" 生活當中,&lt;br /&gt;愛著你自己&lt;br /&gt;愛著愛你的人&lt;br /&gt;愛著神&lt;br /&gt;努力的生活吧。&lt;br /&gt;&lt;br /&gt;胡言亂語,&lt;br /&gt;只不過是趁著下雨的時候,&lt;br /&gt;任由思緒走動一下而已。&lt;br /&gt;&lt;br /&gt;</description><comments>http://kenneth8788.xanga.com/760010931/item/#firstcomment</comments></item><item><title>Wednesday, November 02, 2011</title><link>http://kenneth8788.xanga.com/756322273/item/</link><guid>http://kenneth8788.xanga.com/756322273/item/</guid><pubDate>Wed, 02 Nov 2011 21:48:32 GMT</pubDate><description>&lt;p&gt;人, 一直都有愐懷過去的習慣。&lt;br&gt;曾經, 我這樣....這樣....&lt;br&gt;曾經, 我跟她這樣....這樣....&lt;br&gt;曾經, 我跟他們又這樣....這樣....&lt;br&gt;有人說,&lt;br&gt;回憶就好像夢一樣。&lt;br&gt;的確,&lt;br&gt;有多少個晚上,&lt;br&gt;你的夢, 是回到了那時, 那地, &lt;br&gt;又或是和那些人,&lt;br&gt;在做一些當你有意識下不會放膽作的事?&lt;br&gt;&lt;br&gt;現實, 是殘酷的掙扎。&lt;br&gt;&lt;br&gt;掙扎, 為了生存在殘酷的現實。&lt;br&gt;&lt;br&gt;每天打開雙眼,&lt;br&gt;又仿佛回到了那個受盡限制的框框,&lt;br&gt;那些事情,&lt;br&gt;那些關係,&lt;br&gt;那些說話,&lt;br&gt;把生活的牆,&lt;br&gt;一點一點的壓擠過來,&lt;br&gt;一點, 又一點的.&lt;br&gt;一步, 又一步的....&lt;br&gt;啊... 動不了... 不要...再...&lt;br&gt;就是這個時候,&lt;br&gt;牆上就出現了一道光,&lt;br&gt;當你還沒去想的時候,&lt;br&gt;你的思緒早就條件反射地,&lt;br&gt;順著那光走了出去。&lt;br&gt;&lt;br&gt;那時....那地....那人....&lt;br&gt;&lt;br&gt;夢, 不過是夢。&lt;br&gt;夢, 因為會消失才是夢。&lt;br&gt;正因會消失, 人們才更想抓住更多。&lt;br&gt;&lt;br&gt;砰...砰...砰...砰...&lt;br&gt;又, 回到那現實的牆前。&lt;br&gt;為何不打個電話給那人? 好讓回憶中的, 可以送到現實中?&lt;br&gt;嘟....嘟............喂?&lt;br&gt;天, 談了一番; 地, 說了一頓.....&lt;br&gt;最後, 也是要把電話掛上。&lt;br&gt;&lt;br&gt;砰......&lt;br&gt;又, 回到那現實的牆前。&lt;br&gt;但, 那些牆, 退遠了點嗎?&lt;br&gt;&lt;br&gt;不,&lt;br&gt;是你的感覺輕鬆了。&lt;br&gt;現實的牆一直沒有迫近你,&lt;br&gt;是你的感覺將生活中的事情放大了, 空間少了&lt;br&gt;然後再一直告訴你,&lt;br&gt;是那牆的錯。&lt;br&gt;&lt;br&gt;回憶, 令你分清現在與過去;&lt;br&gt;回憶, 令你將感覺放鬆一下, 又再去用理智的眼睛去看世界;&lt;br&gt;回憶, 不只是為過去的存在。&lt;br&gt;&lt;br&gt;當你還可以將那人從回憶中帶到現實來的時候,&lt;br&gt;好好沉醉一下,&lt;br&gt;感恩一下吧。&lt;/p&gt;</description><comments>http://kenneth8788.xanga.com/756322273/item/#firstcomment</comments></item><item><title>Thursday, August 04, 2011</title><link>http://kenneth8788.xanga.com/753730446/item/</link><guid>http://kenneth8788.xanga.com/753730446/item/</guid><pubDate>Thu, 04 Aug 2011 00:45:18 GMT</pubDate><description>&lt;p&gt;悄然滑落,&lt;br&gt;徐徐的,&lt;br&gt;掉在地上,&lt;br&gt;鏗鏘有聲。&lt;br&gt;___.....&lt;br&gt;那聲音不是文字形容得了,&lt;br&gt;也不是文字形描述得了。&lt;br&gt;因為, &lt;br&gt;曾經載著無數的情懷,&lt;br&gt;無數的期盼,&lt;br&gt;無數的夢想。&lt;br&gt;曾經,&lt;br&gt;的確,&lt;br&gt;已經是曾經,&lt;br&gt;又或許,&lt;br&gt;不再是曾經。&lt;br&gt;&lt;br&gt;天不再藍。&lt;br&gt;&lt;br&gt;雨,&lt;br&gt;靜靜的灑遍大地。&lt;br&gt;那掉在地上的碎片,&lt;br&gt;一點,&lt;br&gt;又一點的,&lt;br&gt;隨流失去。&lt;br&gt;靜靜的, 就靜靜的,&amp;nbsp; 就這樣靜靜的....&lt;/p&gt;</description><comments>http://kenneth8788.xanga.com/753730446/item/#firstcomment</comments></item><item><title>Friday, April 15, 2011</title><link>http://kenneth8788.xanga.com/745745074/item/</link><guid>http://kenneth8788.xanga.com/745745074/item/</guid><pubDate>Fri, 15 Apr 2011 22:58:23 GMT</pubDate><description>回頭一看,&lt;br&gt;看到自己走了多少路;&lt;br&gt;低首一望,&lt;br&gt;看到多少成長的疤痕。&lt;br&gt;看著,&lt;br&gt;想著,&lt;br&gt;回味著。&lt;br&gt;走在一起的時候,&lt;br&gt;感覺依然,&lt;br&gt;但時間,  距離,&lt;br&gt;一切因素,&lt;br&gt;強迫著我們向著不同的世界邁步。&lt;br&gt;每一字一句,&lt;br&gt;見證著這一切,&lt;br&gt;每個時候的每一個字,&lt;br&gt;仿佛都在印證著生命的軌跡,&lt;br&gt;明確指涉而且描繪著現在,&lt;br&gt;那情緒卻延伸至未來。&lt;br&gt;我愛寫,&lt;br&gt;因為寫的目的是溝通,&lt;br&gt;但這過程卻要獨處。&lt;br&gt;就是喜愛這矛盾。&lt;br&gt;情感過了,&lt;br&gt;就回不了來,&lt;br&gt;所以每字每句所裝載的,&lt;br&gt;都是為獨有的人,&lt;br&gt;獨有的事,&lt;br&gt;加上獨有的情感。&lt;br&gt;時間,&lt;br&gt;一直無情的走下去。&lt;br&gt;曾經,&lt;br&gt;天真地以為,&lt;br&gt;只要願意,&lt;br&gt;隨時都可以回頭,&lt;br&gt;重拾慣有的軌跡與生活,&lt;br&gt;唯嘆,&lt;br&gt;事與願違。&lt;br&gt;&lt;br&gt;水流如激箭,&lt;br&gt;人生若浮萍。</description><comments>http://kenneth8788.xanga.com/745745074/item/#firstcomment</comments></item><item><title>Saturday, April 09, 2011</title><link>http://kenneth8788.xanga.com/745269384/item/</link><guid>http://kenneth8788.xanga.com/745269384/item/</guid><pubDate>Sat, 09 Apr 2011 09:38:14 GMT</pubDate><description>&lt;p&gt;打開新聞首頁,&lt;br&gt;不是某人過世, 就是某人得了甚麼甚麼病;&lt;br&gt;不是這裡有著甚麼天災, 就是那兒有著甚麼人禍;&lt;br&gt;不是這人說著甚麼甚麼, 就是那人回應甚麼甚麼...&lt;br&gt;甚麼??&lt;br&gt;為甚麼?&lt;br&gt;世界再也不是一如以往的單純,&lt;br&gt;問題, 不一定伴隨著絕對的答案,&lt;br&gt;就算有著絕對的答案,&lt;br&gt;人們也不是輕易的接受。&lt;br&gt;資訊, 造就機會。&lt;br&gt;機會, 造就財富。&lt;br&gt;但, 人性呢? 良心呢? 對生命的尊重呢?&lt;br&gt;雲飛九霄。&lt;br&gt;其實, 那些不停掙錢的人,&lt;br&gt;又知道用甚麼來承載他們的財富?&lt;br&gt;縱有財富, 人性承載不了;&lt;br&gt;縱有財富, 良心承載不了;&lt;br&gt;縱有財富, 智慧也承載不了。&lt;br&gt;曾經,&lt;br&gt;有一場雨,&lt;br&gt;吞噬了世界上的一切,&lt;br&gt;一隻方舟留下了世界的良心。&lt;br&gt;時間過了,&lt;br&gt;可能有人期待著這場風雨的再來,&lt;br&gt;但,&lt;br&gt;這次,&lt;br&gt;人, 卻要用人心拯救自己。&lt;br&gt;難?&lt;br&gt;在這絕了希望的世界固然很難,&lt;br&gt;但答案不是一直都在嗎?&lt;br&gt;問題,&lt;br&gt;又回到最初。&lt;/p&gt;</description><comments>http://kenneth8788.xanga.com/745269384/item/#firstcomment</comments></item><item><title>Thursday, April 07, 2011</title><link>http://kenneth8788.xanga.com/745166472/item/</link><guid>http://kenneth8788.xanga.com/745166472/item/</guid><pubDate>Thu, 07 Apr 2011 23:03:44 GMT</pubDate><description>好久不見了,&lt;br&gt;還好吧?&lt;br&gt;的確,&lt;br&gt;荒廢了許久,&lt;br&gt;並不是不提筆,&lt;br&gt;而是,&lt;br&gt;每次把筆提在半空,&lt;br&gt;筆尖,&lt;br&gt;許久都沒能落下。&lt;br&gt;墨,&lt;br&gt;一滴,&lt;br&gt;一滴, 又一滴的,&lt;br&gt;落在原稿紙上,&lt;br&gt;然後,&lt;br&gt;又除除的,&lt;br&gt;消失在原稿紙中,&lt;br&gt;一點也不留痕。&lt;br&gt;那怕會弄髒,&lt;br&gt;那怕會寫得一榻糊塗,&lt;span style="font-weight: bold;"&gt;&lt;/span&gt;&lt;br&gt;一點,&lt;br&gt;一點就好,&lt;br&gt;就落下一點淺淺的墨水,&lt;br&gt;留下還是活著的証據。</description><comments>http://kenneth8788.xanga.com/745166472/item/#firstcomment</comments></item><item><title>Tuesday, June 29, 2010</title><link>http://kenneth8788.xanga.com/729377502/item/</link><guid>http://kenneth8788.xanga.com/729377502/item/</guid><pubDate>Tue, 29 Jun 2010 07:04:36 GMT</pubDate><description>&lt;TABLE style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-COLLAPSE: collapse; BORDER-TOP: medium none; BORDER-RIGHT: medium none; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-yfti-tbllook: 1184; mso-padding-alt: 0cm 5.4pt 0cm 5.4pt" class=MsoTableGrid border=1 cellSpacing=0 cellPadding=0&gt;&lt;TBODY&gt;&lt;TR style="mso-yfti-irow: 0; mso-yfti-firstrow: yes"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1" vAlign=top width=168&gt;&lt;P style="TEXT-ALIGN: center; LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=center&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Drug&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1" vAlign=top width=400&gt;&lt;P style="TEXT-ALIGN: center; LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=center&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Function&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 1"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Isoprenaline&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Non selective Beta adrenoceptor agonist&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 2"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Phentolamine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Non selective Alpha adrenoceptor agonist&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 3"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Propranolol&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Beta Adrenoceptor antagonist&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 4"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Prazosin&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt; tab-stops: 155.5pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Alpha 1 Adrenoceptor Antagonist&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 5"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Salbutamol&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Beta 2 Adrenoceptor Agonist&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 6"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Phenylephrine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Alpha 1 Adrenoceptor Agonist&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 7"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Tyramine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Indirectly acting sympathomimetic&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 8"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Carbachol&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Muscarinic and Nicotinic receptor agonist&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 9"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Methacholine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Selective Muscarinic receptor agonist&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 10"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Hexamethonium&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Ganglionic nicotinic receptor Antagonist&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 11"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Tubocurarine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Non depolarising neuromuscular blocking drug&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 12"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Suxamethonium&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Depolarising neuromuscular blocking drug&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 13"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Clonidine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Alpha 2 adrenoceptor agonist&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 14"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Atropine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Muscarinic Antagoinist&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 15"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Idazoxan&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Alpha 2 adrenoceptor antagonist&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 16"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Amphetamine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Indirectly acting sympathomimetic&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 17"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Methoxamine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Alpha Adrenergic Receptor agonist&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 18"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Phenoxybenzamine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Non competitive irrecersivle blocker Alpha adrenocptors&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 19"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Methyldopa&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Rise Alpha methyl-noradrenalin, stimulus alpha 2&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 20"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Hemicholinium&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Ach precursor (inhibit Choline)&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 21"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Neostigmine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Anticholinesterase (inhibit Ach breakdown)&lt;BR&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;non-polarizing neuromuscular Drug&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 22"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Nicotine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Activator of Nicotinic receptor&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 23"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Hyoscine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Muscarinic Receptor Antagonist&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 24"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Phenoxybenzamine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Irreversible Alpha 1 Blocker&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 25"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Mepyramine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;H&lt;SUB&gt;1&amp;shy;&lt;/SUB&gt; antagonist , H&lt;SUB&gt;1&lt;/SUB&gt; antihistamine (1&lt;SUP&gt;st&lt;/SUP&gt; Generation)&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 26"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Histamine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;H&lt;SUB&gt;1 2 3&lt;/SUB&gt; Agonist&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 27"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;2methyl HA&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;H&lt;SUB&gt;1 &lt;/SUB&gt;Agonist&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 28"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Cimetidine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;H&lt;SUB&gt;2&lt;/SUB&gt; Antagonist&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 29"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Thioperamide&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;H&lt;SUB&gt;3 &lt;/SUB&gt;Antagonist&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 30"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Loratadine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;H&lt;SUB&gt;1&lt;/SUB&gt; antihistamine (2&lt;SUP&gt;nd&lt;/SUP&gt; Generation)&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 31"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Fexofenadine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;H&lt;SUB&gt;1&lt;/SUB&gt; antihistamine (2&lt;SUP&gt;nd&lt;/SUP&gt; Generation)&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 32"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Imipramine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;5HT (Tricyclic antidepressants)&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 33"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Fluoxetine&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Selective Serotonin Reuptake inhibitor (SSRIs) 5HT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Block the membrane transporter (Antidepressant)&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 34"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Metoclopramide&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;5HT&lt;SUB&gt;4&lt;/SUB&gt; receptor agonist &lt;/FONT&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; FONT-SIZE: 12pt; mso-fareast-language: ZH-HK; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-char-type: symbol; mso-symbol-font-family: Wingdings"&gt;&lt;SPAN style="mso-char-type: symbol; mso-symbol-font-family: Wingdings"&gt;à&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt; gastric emptying&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 35"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Ondansetron&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;5HT&lt;SUB&gt;3&lt;/SUB&gt; receptor antagonist &lt;/FONT&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; FONT-SIZE: 12pt; mso-fareast-language: ZH-HK; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-char-type: symbol; mso-symbol-font-family: Wingdings"&gt;&lt;SPAN style="mso-char-type: symbol; mso-symbol-font-family: Wingdings"&gt;à&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt; emesis (vomit)&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 36"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Imip&lt;B style="mso-bidi-font-weight: normal"&gt;ramine&lt;/B&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Antidepressant (Block the uptake of 5HT) &lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 37"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Aliskiren&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Competitive inhibitor of human rennin&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;TR style="mso-yfti-irow: 38; mso-yfti-lastrow: yes"&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 125.9pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=168&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;Captopril&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 300.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=400&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-fareast-language: ZH-HK"&gt;&lt;FONT face=Calibri&gt;ACE inhibitor&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;</description><comments>http://kenneth8788.xanga.com/729377502/item/#firstcomment</comments></item><item><title>Saturday, February 27, 2010</title><link>http://kenneth8788.xanga.com/722625545/item/</link><guid>http://kenneth8788.xanga.com/722625545/item/</guid><pubDate>Sat, 27 Feb 2010 11:06:09 GMT</pubDate><description>&lt;P&gt;明天是15 了....&lt;/P&gt;</description><comments>http://kenneth8788.xanga.com/722625545/item/#firstcomment</comments></item><item><title>Tuesday, February 16, 2010</title><link>http://kenneth8788.xanga.com/721989520/item/</link><guid>http://kenneth8788.xanga.com/721989520/item/</guid><pubDate>Tue, 16 Feb 2010 08:27:40 GMT</pubDate><description>生活,&lt;BR&gt;要漸漸的慢下來,&lt;BR&gt;時間,&lt;BR&gt;一點一點的流過。&lt;BR&gt;明天會怎樣?&lt;BR&gt;不用擔心,&lt;BR&gt;神說: 有我在。&lt;BR&gt;&lt;BR&gt;那就好了。</description><comments>http://kenneth8788.xanga.com/721989520/item/#firstcomment</comments></item></channel></rss>
